U.S. Unfractionated Heparin Market Exclusivity – Industry will Drive Huge ROI at US$ 501.5 Million during 2019 to 2027, owing to Increasing Prevalence of Thromboembolism

Impact Analysis of Covid-19

The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.

Request FREE Sample

According to The U.S. Unfractionated Heparin Market Report, by Source (Porcine and Bovine), by Injection Type (IV Injection and Subcutaneous Injection), and by Disease Indication (Venous Thromboembolism, Cardioversion of Atrial Fibrillation, and Pulmonary Embolism & Arterial Embolism), published by Coherent Market Insights, the U.S. unfractionated heparin market was valued at US$ 335.4 million in 2018 and is expected to exhibit a CAGR of 4.5% over the forecast period (2019 – 2027).

Increasing prevalence of thromboembolic diseases is expected to boost growth of the U.S. unfractionated heparin market over the forecast period. For instance, according to the Circulation Research Journal, a journal of the American Heart Association (AHA), in 2016, in the U.S., age-stratified incidence of venous thromboembolism was 143 per 100,000 among people of age 40 to 49 years, 200 per 100,000 among people of age 50 to 59 years, 391 per 100,000 among people of age 60 to 69 years, 727 per 100,000 among people of age 70 to 79 years, and 1,134 per 100,000 among people of age ≥80 years.

Read Press Release: https://www.coherentmarketinsights.com/press-release/us-unfractionated-heparin-market-2585

Moreover, increasing geriatric population and incidence of obesity is also expected to aid in growth of the market. For instance, according to the U.S. Census Bureau, the U.S. geriatric population is expected to reach 77 million by 2034. Moreover, according to the Centers of Disease Control and Prevention, Behavioral Risk Factor Surveillance System, 2018, 71424.3 thousand people in the U.S. suffer from obesity.

Favorable regulatory scenario is expected to offer lucrative growth opportunity for players in the U.S. unfractionated heparin market. For instance, in September 2019, the U.S. Food and Drug Administration (FDA) directed that all forms of imported heparin are subjected to compliance testing, in order to reduce risk of complication such as heparin induced thrombocytopenia and deaths associated with imported heparin.

Among source, porcine segment accounted for the largest market share in the U.S. unfractionated heparin market in 2018. Porcine, is the only U.S. Food and Drug Administration (FDA) approved source for manufacturing of heparin.

Among injection type, IV injection segment accounted for the largest market share in the U.S. unfractionated heparin market in 2018. This is attributed to increasing production of injectables. For instance, in September 2016, Baxter International Inc. acquired Claris Injectable, an India-based generic injectable pharmaceutical company, to increase the production of injectable such as anesthesia and analgesics, anti-infective, renal and critical care products.

Apply Promo Code “STAYHOME” And Get Instant Discount Of USD 1000
Buy Now This Premium Report to Grow your Business @ https://www.coherentmarketinsights.com/insight/buy-now/3187

Among disease indication, venous thromboembolism segment accounted for the largest market share in the U.S. unfractionated heparin market in 2018. This is attributed to high incidence of thromboembolism. For instance, according to the National Center on Birth Defects and Developmental Disabilities, a part of Centers for Disease Control and Prevention, March 2019, venous thromboembolism (VTE) is the foremost cause of preventable hospital death in the U.S. Around 5.0% to 8.0% of the U.S. population has one of the several genetic risk factors.

Major players in the market are focused on adopting M&A strategies to expand their product portfolio. For instance, in July 2016, Nichi-Iko Pharmaceutical Co., Ltd acquired Sagent Pharmaceuticals, Inc., a U.S.-based manufacturer of pharmaceutical injectable, valued at US$ 736 million. This acquisition enhanced Nichi-Iko’s presence in the U.S. market to commercialize its biosimilar product portfolio.

Key Takeaways:

• The U.S. unfractionated heparin market is expected to exhibit a CAGR of 4.5% over the forecast period
• Major players operating in the U.S. unfractionated heparin market include Pfizer, Inc., Sagent Pharmaceuticals, Inc., B. Braun Melsungen AG, Baxter International Inc., and Bayer AG

Other Related Reports:

Heparin Market, by Product Type (Unfractionated Heparin (UH), Low Molecular Weight Heparin (LMWH), and Ultra-low Molecular Weight Heparin (ULMW)), by Dosage Form (Injection, and Solutions), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Size, Share, Outlook, and Opportunity Analysis, 2018 – 2026

Unfractionated Heparin Market, By Source (Bovine and Porcine), By Application (Deep Vein Thrombosis, Pulmonary Embolism, Arterial Embolism, and Others), By End User (Hospitals, Clinics, Ambulatory Surgical Centers, and Academic and Research Organizations), and By Geography – Global Industry Insights, Trends, Outlook, and Opportunity Analysis, 2018-2026

Europe Heparin Market, By Product Type (Low Molecular Weight Heparin, Unfractionated Heparin, Ultra Low Molecular Weight Heparin), By End User (Hospitals, Blood and Stem Cell Bank, Others (Laboratories, Acute Care Centers)), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East & Africa ) – Size, Share Outlook, and Opportunity Analysis, 2020 – 2027

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.

To know more about us, please visit our website – www.coherentmarketinsights.com

Contact:

Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837

This content has been distributed via CDN Newswire press release distribution service. For press release enquires please mail us at contact@cdnnewswire.com.